Supplementary Figure 1

Published: 21 March 2019| Version 3 | DOI: 10.17632/ckz2ss9njx.3
Roland Grenningloh


Supplementary figures from Danka Svecova, Martin W. Lubell, Florence Casset-Semanaz, Harald Mackenzie, Roland Grenningloh, James G. Krueger 'A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti interleukin-17A/F Nanobody®, in moderate-to-severe psoriasis' accepted for publication in the Journal of the American Academy of Dermatology